NBTX
NanobiotixDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive pivotal/clinical outcomes and a clear regulatory path drive rapid re-rating; partnerships or licensing could accelerate adoption.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.9.
What can break
Failed pivotal trial or negative clinical data
Momentum
95
Value
41
Sentiment
7
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.53 · Bull $32.30 · Bear $8.61
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-16 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $26.73
Why
Momentum95 · Δ7d -1.9
Value41 · Δ7d +0.1
Sentiment7 · Δ7d +5.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
95
34% active weight
Current posture
7d trendFlat
Δ7d
-1.9
Δ21d
+1.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
7
33% active weight
Current posture
7d trendImproving
Δ7d
+5.0
Δ21d
+5.0
Why this grade
Composite grade D. Momentum 95.1 / Value 41.1 / Sentiment 6.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.94B
Beta
0.18
Shares Out
48.21M
P/E (TTM) · Derived
-23.7
P/S (TTM)
89.51
P/FCF (TTM) · Derived
-55.41
Rev YoY
-39.5%
EPS YoY
+75.5%
Gross Margin
-
Op Margin
-597.9%
Net Debt
$1.26M
Current Ratio
0.63
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology